ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
CordenPharma has expanded oligonucleotide active pharmaceutical ingredient manufacturing capacity at its Boulder, Colo., plant. The German company, which purchased the site from Roche in 2011, says the facility now can synthesize up to 500 kg of oligonucleotides per year, making it one of the world’s largest oligonucleotide manufacturing sites.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X